FDA investigating pancreatic toxicity of antidiabetics

FDA said it is evaluating the potential pancreatic toxicity of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The agency said unpublished data from undisclosed academics showed the Type II diabetes therapies may be associated with an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia. ...